Roni Atalay1, Süleyman Sayar2, Fatma Gülçiçek Ayrancı3, Şüheda Çakmak4, İbrahim Halil Tanboğa5, Levent Doğanay2, Kamil Özdil2. 1. Departmant of Gastroenterology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey. 2. Departmant of Gastroenterology, Ümraniye Teaching and Research Hospital, University of Health Sciences, İstanbul, Turkey. 3. Department of Pathology, Ümraniye Teaching and Research Hospital, University of Health Sciences, İstanbul, Turkey. 4. Department of Internal Medicine, Ümraniye Teaching and Research Hospital, University of Health Sciences, İstanbul, Turkey. 5. Department of Biostatistics, Nişantaşı University, İstanbul, Turkey.
Abstract
BACKGROUND: The effect of hepatic steatosis on the response to antiviral therapy administered in chronic hepatitis B patients is yet to be clarified. In this study, our aim was to determine the effect of hepatic steatosis on the virological response in chronic hepatitis B patients who were treated with entecavir or tenofovir disoproxil fumarate. METHODS: This retrospective cohort study was performed using the data of liver biopsy-proven chronic hepatitis B patients with or without hepatic steatosis, who received entecavir or tenofovir disoproxil fumarate treatment between 2012 and 2017. The undetectable serum hepatitis B virus deoxyribonucleic acid level under treatment was defined as the complete virological response. The predictors of virological response were determined, and it was checked whether the virological response was affected by hepatic steatosis in chronic hepatitis B patients who have undergone entecavir or tenofovir disoproxil fumarate treatment. RESULTS: A total of 324 chronic hepatitis B patients, of which 203 (63%) were males, were included in the study. The median age of the patients was 42 years (range: 35-51 years). Hepatic steatosis was observed in 25% of the patients, and steatohepatitis in 4%. The median time to complete virological response was found to be 6 months (range: 3-9 months). In the full analysis model, the log hepatitis B virus deoxyribonucleic acid was determined as the factor most associated with virological response (P < .001). No statistically signifi- cant relationship was detected between hepatic steatosis and virological response (P = .409). CONCLUSION: Concomitant hepatic steatosis has no significant impact on the virological response in chronic hepatitis B patients who have undergone entecavir or tenofovir disoproxil fumarate treatment.
BACKGROUND: The effect of hepatic steatosis on the response to antiviral therapy administered in chronic hepatitis B patients is yet to be clarified. In this study, our aim was to determine the effect of hepatic steatosis on the virological response in chronic hepatitis B patients who were treated with entecavir or tenofovir disoproxil fumarate. METHODS: This retrospective cohort study was performed using the data of liver biopsy-proven chronic hepatitis B patients with or without hepatic steatosis, who received entecavir or tenofovir disoproxil fumarate treatment between 2012 and 2017. The undetectable serum hepatitis B virus deoxyribonucleic acid level under treatment was defined as the complete virological response. The predictors of virological response were determined, and it was checked whether the virological response was affected by hepatic steatosis in chronic hepatitis B patients who have undergone entecavir or tenofovir disoproxil fumarate treatment. RESULTS: A total of 324 chronic hepatitis B patients, of which 203 (63%) were males, were included in the study. The median age of the patients was 42 years (range: 35-51 years). Hepatic steatosis was observed in 25% of the patients, and steatohepatitis in 4%. The median time to complete virological response was found to be 6 months (range: 3-9 months). In the full analysis model, the log hepatitis B virus deoxyribonucleic acid was determined as the factor most associated with virological response (P < .001). No statistically signifi- cant relationship was detected between hepatic steatosis and virological response (P = .409). CONCLUSION: Concomitant hepatic steatosis has no significant impact on the virological response in chronic hepatitis B patients who have undergone entecavir or tenofovir disoproxil fumarate treatment.
Authors: Rocío Aller; Conrado Fernández-Rodríguez; Oreste Lo Iacono; Rafael Bañares; Javier Abad; José Antonio Carrión; Carmelo García-Monzón; Joan Caballería; Marina Berenguer; Manuel Rodríguez-Perálvarez; José López Miranda; Eduardo Vilar-Gómez; Javier Crespo; Miren García-Cortés; María Reig; José María Navarro; Rocío Gallego; Joan Genescà; María Teresa Arias-Loste; María Jesús Pareja; Agustín Albillos; Jordi Muntané; Francisco Jorquera; Elsa Solà; Manuel Hernández-Guerra; Miguel Ángel Rojo; Javier Salmerón; Llorenc Caballería; Moisés Diago; Esther Molina; Ramón Bataller; Manuel Romero-Gómez Journal: Gastroenterol Hepatol Date: 2018-04-07 Impact factor: 2.102